Show simple item record

dc.contributor.authorGunning, AC
dc.contributor.authorFryer, V
dc.contributor.authorFasham, J
dc.contributor.authorCrosby, AH
dc.contributor.authorEllard, S
dc.contributor.authorBaple, EL
dc.contributor.authorWright, CF
dc.date.accessioned2020-09-02T14:22:05Z
dc.date.issued2020-08-25
dc.description.abstractBackground Pathogenicity predictors are integral to genomic variant interpretation but, despite their widespread usage, an independent validation of performance using a clinically relevant dataset has not been undertaken. Methods We derive two validation datasets: an ‘open’ dataset containing variants extracted from publicly available databases, similar to those commonly applied in previous benchmarking exercises, and a ‘clinically representative’ dataset containing variants identified through research/diagnostic exome and panel sequencing. Using these datasets, we evaluate the performance of three recent meta-predictors, REVEL, GAVIN and ClinPred, and compare their performance against two commonly used in silico tools, SIFT and PolyPhen-2. Results Although the newer meta-predictors outperform the older tools, the performance of all pathogenicity predictors is substantially lower in the clinically representative dataset. Using our clinically relevant dataset, REVEL performed best with an area under the receiver operating characteristic curve of 0.82. Using a concordance-based approach based on a consensus of multiple tools reduces the performance due to both discordance between tools and false concordance where tools make common misclassification. Analysis of tool feature usage may give an insight into the tool performance and misclassification. Conclusion Our results support the adoption of meta-predictors over traditional in silico tools, but do not support a consensus-based approach as in current practice.en_GB
dc.description.sponsorshipWellcome Trusten_GB
dc.description.sponsorshipDepartment of Healthen_GB
dc.description.sponsorshipHealth Innovation Challenge Funden_GB
dc.identifier.citationPublished online 25 August 2020en_GB
dc.identifier.doi10.1136/jmedgenet-2020-107003
dc.identifier.grantnumberWT200990/Z/16/Zen_GB
dc.identifier.grantnumberWT200990/A/16/Zen_GB
dc.identifier.grantnumberHICF-1009-003en_GB
dc.identifier.grantnumberWT098051en_GB
dc.identifier.urihttp://hdl.handle.net/10871/122685
dc.language.isoenen_GB
dc.publisherBMJ Publishing Groupen_GB
dc.rights© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.en_GB
dc.titleAssessing performance of pathogenicity predictors using clinically relevant variant datasetsen_GB
dc.typeArticleen_GB
dc.date.available2020-09-02T14:22:05Z
dc.identifier.issn0022-2593
dc.descriptionThis is the final version. Available on open access from BMJ Publishing Group via the DOI in this recorden_GB
dc.identifier.journalJournal of Medical Geneticsen_GB
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_GB
dcterms.dateAccepted2020-06-20
exeter.funder::Wellcome Trusten_GB
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2020-06-20
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2020-09-02T14:17:35Z
refterms.versionFCDVoR
refterms.dateFOA2020-09-02T14:22:10Z
refterms.panelAen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. 
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Except where otherwise noted, this item's licence is described as © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.